Skip to content

DE · 4XT.DE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

XPhyto Therapeutics Corp.

$0.37as of 2026-11-13 · Mkt cap 0

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Healthcare · Drug Manufacturers - Specialty & Generic Vancouver, BC V6J 3B1 xphyto.com

How the business is doing

Fiscal 2018–2021, USD

Revenue
$290K
20182021
Net income
-$-20.64M
20182021
Free cash flow
-$-12.61M
20182021
Total equity
$1.67M
20182021

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About XPhyto Therapeutics Corp.

        XPhyto Therapeutics Corp. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

        CEO
        Hugh A. D. Rogers
        Employees
        0
        Beta
        0.15

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.